drugset
drugset / Trial / NCT03379051

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

NCT03379051 ↗

Phase 1/2 Terminated 78 enrolled TG Therapeutics, Inc. James P. Wilmot Cancer Center · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL

Timeline

Start
2018-03-27
Primary completion
2022-05-26
Completion
2022-06-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified — —
Subject Venetoclax Small molecule — Oral
Background Ublituximab Monoclonal antibody — Intravenous
Background Umbralisib Small molecule — Oral

Indications

B-cell chronic lymphocytic leukemia